Inicio>>Signaling Pathways>> Others>>Amifampridine

Amifampridine

Catalog No.GC35318

La amifampridina (3,4-diaminopiridina) es un bloqueador de los canales de potasio (Kv) controlado por voltaje (PCB) activo por vÍa oral, potente y permeable a las células.

Products are for research use only. Not for human use. We do not sell to patients.

Amifampridine Chemical Structure

Cas No.: 54-96-6

Tamaño Precio Disponibilidad Cantidad
10mM (in 1mL DMSO)
52,00 $
Disponible
100mg
46,00 $
Disponible

Tel:(909) 407-4943 Email: sales@glpbio.com

Reseñas de cliente

Based on customer reviews.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Chemical Properties Product Documents Related Products

Amifampridine (3,4-Diaminopyridine) is a drug, predominantly in the treatment of a number of rare muscle diseases.Target: OthersAmifampridine is a drug, predominantly in the treatment of a number of rare muscle diseases. Amifampridine works by blocking potassium channel efflux in nerve terminals so that action potential duration is increased. Ca2+ channels can then be open for a longer time and allow greater acetylcholine release to stimulate muscle at the end plate. A 2005 systematic review from the Cochrane Collaboration found some data favouring its use in LEMS. Amifampridine is also used to treat many of the congenital myasthenic syndromes, particularly those with defects in choline acetyltransferase, downstream kinase 7, and those where any kind of defect causes "fast channel" behaviour of the acetylcholine receptor. From Wikipedia.

[1]. http://en.wikipedia.org/wiki/3,4-Diaminopyridine#cite_note-4

Reseñas

Review for Amifampridine

Average Rating: 5 ★★★★★ (Based on Reviews and 22 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for Amifampridine

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.